ReviewCritical reviews in clinical laboratory sciences
Biomarkers of sepsis.
Review in Critical reviews in clinical laboratory sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 336 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fast Assay for Pathogen Identification and Characterization - Prospective Observational Study
Immune Profile of Patients With Positive Blood Cultures and Multiple Organ Dysfunctions
Electroacupuncture Modulates the Metabolism of SPMs and Ameliorates Respiratory Symptoms and Inflammation in Patients With Sepsis Complicating ARDS
CRP,CRP/Alb Ratio, N/L Ratio in Predictors of Both Systemic Infection and Survival in Patient With Sepsis
The Effect of Extracorporeal Sepsis Adsorption Column Use on Plasma Syndecan-1 Level and Mortality in Sepsis Patients
Electroencephalogram Changes and Cognitive Function Profiles in Sepsis Patients With Different Inflammatory Phenotypes
Who cites it
336 citing papers in PubMed, 2 syntheses or guidelines pooled it, 649 citations in OpenAlex.
- LINC02363: a potential biomarker for early diagnosis and treatment of sepsis.BMC immunology · 2025Pooled it
- Association between circulating cell-free mitochondrial DNA and inflammation factors in noninfectious diseases: A systematic review.PloS one · 2024Pooled it
- Effects of Xuebijing combined with levosimendan on immune function and coagulation function in sepsis patients with myocardial injury.Journal of thrombosis and thrombolysis · 2026Trial
- Xuebijing alleviates septic myocardial injury by inhibiting ferroptosis mediated by the ICAM1/TLR signaling pathway.Histology and histopathology · 2026Article
- Peli1 promotes sepsis-induced inflammation and coagulopathy by maintaining lipg stability in macrophages.Journal of thrombosis and thrombolysis · 2026Article
- Relationship between continuous infusion meropenem PK/PD target attainment and C-reactive protein dynamics in onco-haematologic patients with febrile neutropenia.British journal of clinical pharmacology · 2026Article
- Diagnostic utility of postmortem serum tumor markers for identifying primary malignancies: A forensic evaluation of six markers.Forensic science, medicine, and pathology · 2026Article
- Comparative Analysis of Novel Inflammatory and Nutritional Indices (m-HALP, HALP, SII, SIRI) for Risk Stratification in Septic Patients: A Retrospective Cohort Study.Life (Basel, Switzerland) · 2026Article
- Prognostic Value of 72-h Reassessment Using SOFA Score, C-Reactive Protein, and Lactate in a 72-h Landmark Cohort of Intensive Care Patients with Gram-Negative Sepsis.Medicina (Kaunas, Lithuania) · 2026Article
- Role of Matrix Metalloproteinases and Tissue Inhibitors in Sepsis Pathogenesis.Medical sciences (Basel, Switzerland) · 2026Article
- An explainable machine learning model for early pediatric sepsis prediction using cytokine and routine laboratory data.Pediatric research · 2026Article
- Radiological detection rate and clinical impact of thoracoabdominal computed tomography in suspected infection in the emergency department: a retrospective cohort study.BMC emergency medicine · 2026Article
- Recent advances in the biosensing platforms for sepsis diagnosis.RSC advances · 2026Review
- Serum CCL1 discriminates infectious and sterile systemic inflammation in sepsis and acute pancreatitis.Scientific reports · 2026Article
- Lightweight large language models for early sepsis prediction via a semantic abstraction rule engine.Scientific reports · 2026Article
- The Importance of Plasma Renin Concentrations in Intensive Care Patients with Circulatory Shock.Journal of clinical medicine · 2026Article
- Blood-based biomarkers and delirium in critically ill adults in the ICU: a systematic review.Intensive care medicine experimental · 2026Review
- Applications of Extended Platelet Profiles in Clinical Practice.Diseases (Basel, Switzerland) · 2026Review
- Diagnostic and prognostic utility of neutrophil CD64 and monocyte HLA-DR in adult sepsis patients.BMC research notes · 2026Observational
- A Mini-Review of Point-of-Care C-Reactive Protein Testing in Sepsis in the Emergency Department.EJIFCC · 2026Review
276 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is an unusual systemic reaction to what is sometimes an otherwise ordinary infection, and it probably represents a pattern of response by the immune system to injury. A hyper-inflammatory response is followed by an immunosuppressive phase during which multiple organ dysfunction is present and the patient is susceptible to nosocomial infection. Biomarkers to diagnose sepsis may allow early intervention which, although primarily supportive, can reduce the risk of death. Although lactate is currently the most commonly used biomarker to identify sepsis, other biomarkers may help to enhance lactate's effectiveness; these include markers of the hyper-inflammatory phase of sepsis, such as pro-inflammatory cytokines and chemokines; proteins such as C-reactive protein and procalcitonin which are synthesized in response to infection and inflammation; and markers of neutrophil and monocyte activation. Recently, markers of the immunosuppressive phase of sepsis, such as anti-inflammatory cytokines, and alterations of the cell surface markers of monocytes and lymphocytes have been examined. Combinations of pro- and anti-inflammatory biomarkers in a multi-marker panel may help identify patients who are developing severe sepsis before organ dysfunction has advanced too far. Combined with innovative approaches to treatment that target the immunosuppressive phase, these biomarkers may help to reduce the mortality rate associated with severe sepsis which, despite advances in supportive measures, remains high.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.